Delving into the Latest Updates on LY01620 with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, mRNA vaccine

Synonyms

Target

HPV E6 x HPV E7

Action

inhibitors

Mechanism

E7 inhibitors(Protein E7 inhibitors), HPV E6 inhibitors(HPV E6 inhibitors)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Squamous Intraepithelial Lesions of the Cervix

Inactive Indication-

Originator Organization

Nanjing Geneleap Biotech Co., Ltd.

Active Organization

Nanjing Geneleap Biotech Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1.主要目的：在HPV16阳性经组织学证实为HSIL患者中评价LY01620多次肌肉注射的安全性和耐受性。 2.次要目的：在HPV16阳性经组织学证实为HSIL患者中评价LY01620多次肌肉注射的免疫应答及免疫原性。在HPV16阳性经组织学证实为HSIL的患者中评价LY01620多次肌肉注射的初步有效性。

[Translation]

1. Primary objective: To evaluate the safety and tolerability of multiple intramuscular injections of LY01620 in patients with HPV16-positive histologically confirmed HSIL. 2. Secondary objectives: To evaluate the immune response and immunogenicity of multiple intramuscular injections of LY01620 in patients with HPV16-positive histologically confirmed HSIL. To evaluate the preliminary efficacy of multiple intramuscular injections of LY01620 in patients with HPV16-positive histologically confirmed HSIL.

Start Date-

Sponsor / Collaborator

Nanjing Geneleap Biotech Co., Ltd.

100 Clinical Results associated with LY01620

Login to view more data

100 Translational Medicine associated with LY01620

Login to view more data

100 Patents (Medical) associated with LY01620

Login to view more data

100 Deals associated with LY01620

Login to view more data